DCs from cancer patients are functionally defective, however, molecular mechanisms underlying are poorly understood. In this study, we used the murine 5TGM1 myeloma model to examine the effects and mechanism of tumor-derived factors on the 
INTRODUCTION
DC-based immunotherapy holds great promise for treating malignancies [1] [2] [3] , including multiple myeloma 2, 4 . However, preliminary reports of DC vaccines in human trials have demonstrated minor clinical responses 1, 2 . The lack of effectiveness of DC vaccines in tumor patients may be associated at least in part with defects in DCs [5] [6] [7] [8] . Accumulating evidence show that DCs generated ex vivo from their progenitor cells in tumor patients or tumor-bearing animals are functionally abnormal [5] [6] [7] [8] . Thus, a better understanding of the molecular mechanisms underlying the impairment of DC functions by tumor-derived factors and restoration of functions of DCs from tumor patients will be important for the application of DC-based immunotherapy in multiple myeloma and other malignancies.
The 5T murine model of myeloma, originally described by Radl and coworkers in an inbred substrain of C57 black mice (C57BL/KaLwRij substrain) 9 , offers a unique opportunity for in vivo studies of myeloma biology, drug treatment, and tumor immunology. Several of the 5T myeloma lines closely mimic myeloma disease in humans, with monoclonal gammopathy, marrow replacement, focal osteolytic bone lesions, hind-limb paralysis, and occasionally hypercalcemia 9, 10 . Using this murine myeloma model, the aim of this study was to examine whether and how tumor cells and their derived factors affected the differentiation and generation of DCs, and whether it was possible to restore the function of the cells. Our results show that culture of murine BM cells with myeloma cells, both in a transwell system or direct contact, and with tumor-culture conditioning medium (TCCM) impaired the differentiation and generation of BM-derived DCs (BMDCs), and myeloma-derived cytokines, such as IL-6, IL-10 and TGF-β, were partially responsible. The mitogen-activated protein kinase (MAPK) p38, which was activated in the cultured BM cells by the treatment with myeloma cells or TCCM, play an important and detrimental role in the differentiation of BMDCs.
Inhibiting p38 MAPK activity in BM cells cultured in the presence of TCCM restored the generation of functional BMDCs.
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MATERIALS AND METHODS

Mice, cell lines, and reagents
BALB/c and C57BL/KaLwRij mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and Harlan CPB (Zeist, The Netherlands), respectively. The murine myeloma cell line 5TGM1 11, 12 was kindly provided by Dr. G.R. Mundy at the University of Texas Health Science at San Antonio. The two murine myeloma cell lines MCP-11
and MOPC-315 were purchased from ATCC (Rockville, MD).
The p38 MAPK inhibitors SB203580 and SB202190, p38 MAPK inhibitor III; and JNK inhibitor II were purchased from EMD Biosciences (San Diego, CA). These inhibitors were dissolved in DMSO (Sigma, St. Louis, MO), and the final concentration of DMSO in cultures was 0.05%. IL-6, IL-10, VEGF, MCP-1 and -5, and RANTES, and TGF-β1, as well as their neutralizing or blocking antibodies were purchased from R&D System (Minneapolis, MN).
Preparation of TCCM
5TGM1 cells were cultured in IMDM complete medium and 24 h later supernatants were harvested, filtered, and concentrated 10-fold using an Amicon Ultra Filter (Millipore Corp., Bedford, MA). Concentrated TCCM were aliquoted and stored at -80°C until use.
Unless otherwise noted, all TCCM used in the experiments was from 5TGM1 cells.
Medium control, prepared from freshly prepared IMDM complete medium in the same way as TCCM, and TCCM from the other two murine myeloma cell lines MCP-11 and MOPC-315 were used in thee experiments.
Generation of BMDCs and treatment with myeloma cells
BMDCs were generated as described previously 13 . BM cells were flushed out from tibia and femurs of C57BL/KaLwRij mice, and cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum with addition of 20 ng/ml GM-CSF (R&D Systems). At day (d) 4, 90% of the medium was taken out and replaced with fresh medium containing 10 ng/ml GM-CSF. At d 8, cultures were replaced with fresh medium
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To examine the effects of myeloma cells or their derived factors on the differentiation of BMDCs, TCCM was added to the cell cultures (10% of TCCM to 90% of fresh medium) on d 0, and on d 4 when medium was changed. No additional TCCM was added on d 8.
In other studies, BM cells were cocultured with 5TGM1 (8 × 10 4 cells /ml) placed on a 0.4 μm transwell insert (NUNC, Naperville, IL), or cocultured directly with irradiated 5TGM1 cells (8 x 10 4 /ml). Medium changes and maturation induction were the same as normal BMDCs.
Flow cytometry analysis
BMDCs or cultured cells were incubated with FITC-or PE-conjugated mAbs against 
Detection of cytokine expression and production
Intracellular IL-12 and IL-10 staining for BMDCs and IFN-γ and IL-4 staining for T cells were performed using a Cytofix/Cytoperm kit (BD Biosciences) according to the instruction. Cells (BMDCs or activated T cells) were stained with FITC-labeled antiCD11c mAb or CD3, followed by staining with PE-labeled anti-IL-12, IL-10, IFN-γ or IL-4 (BD Pharmingen), washing, and analysis.
An ELISA for IL-12 and TGF-β1 was used to measure the secreted cytokines.
Supernatants from BM cell cultures at different time points were collected, and the cytokines in the supernatants were quantified using commercially available ELISA kits (R&D Systems).
A cytokine array analysis (RayBiotech, Norcross, GA) was used to examine a broader spectrum of cytokines secreted by different cells. Supernatants from 24-hour culture of 5TGM1 and 4-day cultures of BM cells with or without addition of TCCM were collected Each of the primer sets was confirmed by running samples on agarose gels. β-actin transcript levels were used to normalize the amount of cDNA in each sample. Water controls were always included in each experiment.
Western blotting analysis
To examine intracellular signaling, phosphorylated (p) p38 and pERK, pMEK, pJNK, and pIκB-α were detected as previously described 14 . Samples were subjected to SDS-PAGE, and after transfer to nitrocellulose membrane and subsequent blocking, the membranes were immunoblotted with respective antibodies (Cell Signaling, Inc. Beverly, MA), and visualized with alkaline phosphatase-conjugated secondary antibodies, followed by an enhanced chemiluminescence (Bio-Rad Laboratories, Hercules, CA) and autoradiography.
To examine p38 activity in the cells, a p38 functional assay kit (US Biological, Swampscott, MA) was used, which is to examine the capacity of p38 to phosphorylate one of its substrates, ATF-2 by Western blotting. Non-phosphorylated p38 was examined and serve as control for cell lysate proteins. µl of the supernatants were collected, and radioactivity was measured. Percent specific lysis was calculated using the following formula: percent specific lysis = (experimental counts -spontaneous counts)/ (maximal counts -spontaneous counts).
Statistical analysis
Student's t test was used for the comparison of various experimental groups, and the Kaplan-Meier test for comparison of mouse survival. Significance was set at p < 0.05.
RESULTS
Phenotype, cytokine expression, and function of BMDCs in cultures with or without myeloma cells or their-derived factors
To determine the effects of 5TGM1 myeloma cells on the phenotype of DCs, BM cells were cultured with GM-CSF in the presence or absence of TCCM, or with 5TGM1 cells in a transwell system or in direct contact with irradiated 5TGM1 cells. In most of the experiments described below, d 10 cultured cells (mature BMDCs) were used for the analyses. The expression of DC-related surface molecules CD86 and MHC class II were significantly inhibited by the presence of myeloma cells or TCCM (p < 0.05 to p < 0.01; Figure 1A ), indicating that soluble factors secreted by the myeloma cells, rather than a direct cell contact, impaired the phenotype of cultured BMDCs.
To verify these results, we tested TCCM from two other myeloma cell lines, MPC-11 and MOPC-315. Indeed, addition of 10% of TCCM from these two cell lines also were able 
Identification of tumor-derived factors affecting BMDC differentiation
To determine the soluble factors responsible for the observed effects, a cytokine array analysis was used to examine cytokines present in the culture media of 5TGM1, normal
BMDCs, and TCMM-treated BMDCs. As shown in Figure 3A , 5TGM1 cells secrete relatively large amounts of regulated on activation, normal T-cell expressed and secreted (RANTES), IL-10, vascular endothelial growth factor (VEGF), and soluble TNF receptor-1 (sTNFR1); and modest amounts of IL-6 and monocyte chemotactic protein (MCP)-1. As this cytokine array does not include TGF-β, which might be an important and negative regulator of DC differentiation [18] [19] [20] [21] [22] , RT-PCR was employed to detect TGF-β mRNA expression in 5TGM1 myeloma cells. As shown in Figure 3B , TGF-β mRNA was detected. Secretion of this cytokine, detected by an ELISA kit for TGF-β1 quantification (R&D Systems) showed that low level of TGF-β1 protein was in the culture medium of 5TGM1 cells (p < 0.05; Figure 3C ). The same assays were also used to detect cytokine expression and production in other two myeloma-cell lines MPC-11
and MOPC-315 and their conditioning media. As exemplified by the results of RT-PCR, similar levels of IL-6, IL-10, TGF-β, and VEGF mRNA were detected in all three myeloma cell lines ( Figure 3B ).
The array analysis revealed that during differentiation, cultured BM cells secreted a low level of IL-6 and modest levels of IL-12, MCP-1, and RANTES ( Figure 3A) , whereas in cultures with the addition of TCCM, the levels of G-CSF, IL-6, MCP-5, RANTES, sTNFR1, TNF-α, and VEGF were significantly increased (p <0.05 to p < 0.01). Hence, these cytokines might have contributed to the detrimental effects via an autocrine action on the cultured BMDCs.
We next determined which cytokines were important for impairing BMDC differentiation. We first added these cytokines individually or in combination to cell culture at a final concentration of 10 ng/ml except TGF-β, which was 5 ng/ml (these may be 2-to 10-fold higher than levels detected in TCCM; see Figures 3 and 6) . Cultures with the addition of 10% TCCM served as a positive control. As shown in Figure 4A , adding IL-6, TGF-β, and more importantly IL-10, or a combination of these three cytokines impaired the phenotype of the cultured cells (p < 0.05 to p < 0.01), while adding RANTES, MCP-1, and VEGF had no effects (data not shown).
Second, neutralizing antibodies against these cytokines, IL-6, IL-10, TGF-β, VEGF, RANTES, and MCP-1 (20 μg/ml), each or in a combination of all these antibodies, were added to cell cultures containing 10% TCCM. As shown in Figure 4B , neutralizing antibodies against IL-6, TGF-β, or IL-10 in particular partially restored the phenotype of BMDCs. The same results were also obtained with a combination of all the antibodies.
Neutralizing antibodies against other cytokines, such as VEGF, RANTES, and MCP-1, had no effect (data not shown). Thus, these results indicate that these three cytokines, especially IL-10 are partially responsible for retarding the differentiation of BMDCs.
Cell signaling pathways induced by TCCM
To examine signaling pathways involved in TCCM-treated cells, cell lysates from d 5 cultures were prepared for the analyses. As shown in Figure 4C , an increased expression of pp38 and pJNK, and a decreased level of pERK and pMEK were observed in cells 
Inhibiting p38 MAPK restored the phenotype and function of TCCM-treated
BMDCs
To examine whether activation of p38 MAPK suppressed differentiation of BMDCs, a p38 inhibitor SB203580 was added to the cells at the beginning of the cultures, without further addition of inhibitors thereafter at medium changes. As shown in Figure 5A , in cultures without TCCM, inhibiting p38 further enhanced the upregulation of CD86 and MHC class II expression, whereas in cultures with the addition of TCCM, the inhibitor not only restored the phenotype ( Figure 5A ) and the secretion of IL-12 ( Figure 5B ), but also the allostimulatory capacity of the cells ( Figure 5C ). To confirm these results, two other selective p38 inhibitors, SB202190 and p38 inhibitor III were also used. Similar to SB203580, these two inhibitors also restored the phenotype (Figure 5D ), IL-12 secretion, We next examined signaling molecules and cytokine secretion profiles in cells treated with p38 inhibitor SB203580. As shown in Figure 6A , inhibiting p38 in TCCM-treated cells restored the protein levels of pERK and pMEK, suggesting that SB203580 abrogated TCCM-mediated inhibition on MEK/ERK signaling pathway. As SB203580
binds to the ATP-binding pocket of p38 kinase and inhibits its activity but does not prevent it from being phosphorylated 23 , the expression of pp38 in TCCM-treated cells was not affected by the inhibitor (Figure 6B ). To verify that p38 MAPK activity was indeed inhibited by SB203580, a p38 functional assay that is to test the capacity of pp38
to phosphorylate its substrate activating transcription factor 2 (ATF-2), was used. As shown in Figure 6B , in normal, differentiating BM cells in which a low level of pp38 was detected, a low level of phosphorylation of ATF-2 induced by pp38 was observed in the in vitro assay. TCCM treatment increased the levels of pp38, and phosphorylation of ATF-2. SB203580 treatment of TCCM-treated cells did not affect the expression of pp38 but its capacity to phosphorylate ATF-2 was significantly reduced, thus confirming the inhibition of pp38 activity by the treatment.
Cytokine profiles of the cells were examined by RT-PCR and cytokine array analysis. As shown in Figure 6C , while TCCM treatment increased mRNA expression of IL-6, IL-10, and TGF-β in treated cells, addition of the inhibitor significantly reduced mRNA expression of these cytokines in TCCM-treated cells. SB203580 alone had not effect.
Furthermore, as shown in Figure 6D using the cytokine array analysis to examine a broad spectrum of cytokines, the p38 inhibitor successfully reduced the secretion of cytokines including IL-6, IL-10, TNF-α, and VEGF in TCCM-treated cells. Secretion of TGF-β1, measured by an ELISA, was also significantly reduced in TCCM-treated cells ( Figure 6E ).
In vivo capacity of normal BMDCs and TCCM-treated cells to immunize against KLH and myeloma-derived Id
To compare the efficiency of the cells to prime tumor-specific immunity in vivo, normal mature BMDCs and other treated cells pulsed with Id-KLH conjugates were used as vaccines to immunize C57BL/KaLwRij mice. As shown in Figure 7 , vaccination with Figure 7D ).
To examine the capacity of these cells to treat established myeloma, mice were first inoculated with 5TGM1 cells. Ten days later when circulating IgG2b Id was increased by 1.5-to 2-fold, three weekly DC vaccinations were given. As shown in Figure 7E As our results indicated that soluble factors were responsible for retarding the differentiation of BMDCs, various assays were employed to detect and identify the contributing cytokines. Since high levels of IL-6, IL-10, VEGF, G-CSF, TNF-α, RANTES, MCP-1 and MCP-5, and TGF-β were detected in TCCM or the supernatant of TCCM-treated BMDCs, we show, using exogenous cytokines and neutralizing antibodies, that IL-6, TGF-β, and especially IL-10 might partially be responsible for the inhibitory activity of TCCM on the differentiation of BMDCs. VEGF, which was previously shown to be responsible for inhibiting the functional maturation of dendritic phenotype. However, of interest and importance is our finding that the defects in DCs can be corrected, such as inhibiting p38 MAPK during DC differentiation. Such findings warrant further studies to examine the applicability of this approach in the preparation of DC vaccines for cancer patients.
In conclusion, this study demonstrates that tumor cells or their derived cytokines suppressed the differentiation and generation of BMDCs. In contrast with previous reports in which VEGF was identified as the major player in solid tumors 6, 18, 33 , the current study identified myeloma-derived IL-6, TGF-β, and more importantly IL-10 as the cytokines that suppress the differentiation of BMDCs. More importantly, we also identified p38 MAPK as a novel target for intervention and showed that inhibiting p38
MAPK activity during DC differentiation can restore the phenotype, cytokine secretion, and function of BMDCs. We believe that this study is the first to show that blockage of p38 MAPK can improve the quality of DCs obtained from cancers. Further preclinical studies are needed to examine the applicability of this approach to preparing DC vaccines for immunotherapy in cancer patients. MOPC-315 A B 
